Literature DB >> 23379483

Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis.

Chris S Baker1, Peter A Foley, Anna Braue.   

Abstract

BACKGROUND/
OBJECTIVES: Internationally, the understanding of psoriasis has advanced in recent years to the point now where it is no longer considered a benign or cosmetic skin condition but a systemic, immune-mediated disease associated with significant comorbidities and considerable detriment to quality of life. The aim of this study was to gain a better understanding of the physical, psychosocial and medical burden of psoriasis on Australian adults and the impact on health status.
METHODS: Two large-scale multi-centre cross-sectional studies of Australian adults with psoriasis were conducted during 2010 and 2011, with the participation of a national patient representative group (Psoriasis Australia). The studies were based on detailed questionnaires that were self-completed by individuals with psoriasis.
RESULTS: A total of 362 and 330 completed surveys were received in 2010 and 2011, respectively. A significant physical, psychosocial and medical burden was reported by the respondents. It was noteworthy that patients reported actively concealing their disease from the general public (83%), work colleagues (65%), friends (58%), employers (49%), family (40%), close friends (39%) and spouse/partner (20%). The mean five-dimension European quality of life (EQ-5D) score for the 2011 cohort was 0.73, representing a significant impact on their HRQoL. The presence of comorbidities, found in three-quarters of the cohort, was associated with an even greater detriment to their HRQoL (mean score 0.64).
CONCLUSIONS: Psoriasis imposes a significant psychosocial burden on the lives of patients, including a profound impact upon their personal and professional relationships, social interactions and quality of life, to a degree comparable to other serious chronic conditions. This study highlights the importance of collaboration between primary and specialist health-care providers in developing patient management strategies that address the spectrum of physical and psychological manifestations associated with psoriasis.
© 2013 AbbVie Pty Ltd Australasian Journal of Dermatology © 2013 The Australasian College of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23379483     DOI: 10.1111/ajd.12010

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  7 in total

1.  The challenges of assessing patients' medication beliefs: a qualitative study.

Authors:  Rachael J Thorneloe; Christopher E M Griffiths; Darren M Ashcroft; Lis Cordingley
Journal:  BMC Health Serv Res       Date:  2017-02-07       Impact factor: 2.655

2.  'New to me': changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study.

Authors:  P A Nelson; K Kane; C J Pearce; C Bundy; A Chisholm; R Hilton; R Thorneloe; H Young; C E M Griffiths; L Cordingley
Journal:  Br J Dermatol       Date:  2017-08-17       Impact factor: 9.302

3.  Enhancing self-compassion in individuals with visible skin conditions: randomised pilot of the 'My Changed Body' self-compassion writing intervention.

Authors:  Kerry A Sherman; Tegan Roper; Christopher Jon Kilby
Journal:  Health Psychol Behav Med       Date:  2019-03-18

4.  Discovery in genetic skin disease: the impact of high throughput genetic technologies.

Authors:  Thiviyani Maruthappu; Claire A Scott; David P Kelsell
Journal:  Genes (Basel)       Date:  2014-08-04       Impact factor: 4.096

5.  'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study.

Authors:  Pauline A Nelson; Karen Kane; Anna Chisholm; Christina J Pearce; Christopher Keyworth; Martin K Rutter; Carolyn A Chew-Graham; Christopher E M Griffiths; Lis Cordingley
Journal:  Health Expect       Date:  2015-09-04       Impact factor: 3.377

6.  Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis.

Authors:  R J Thorneloe; C Bundy; C E M Griffiths; D M Ashcroft; L Cordingley
Journal:  Br J Dermatol       Date:  2016-12-17       Impact factor: 9.302

Review 7.  Improving patient outcomes in psoriasis: strategies to ensure treatment adherence.

Authors:  Oriol Yélamos; Sandra Ros; Lluís Puig
Journal:  Psoriasis (Auckl)       Date:  2015-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.